Impaired absorption of rifabutin by concomitant administration of didanosine.
Marzolini
C
C
Chave
J P
JP
Telenti
A
A
Brenas-Chinchon
L
L
Biollaz
J
J
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000493:pharmacokinetics*; D016049:Didanosine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy; D015497:HIV-1; D006801:Humans; D007408:Intestinal Absorption; D008297:Male; D008875:Middle Aged; D009164:Mycobacterium Infections / Q000188:drug therapy; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D017828:Rifabutin / Q000008:administration & dosage / Q000493:pharmacokinetics*
D019380:Anti-HIV Agents; D000904:Antibiotics, Antitubercular; D018894:Reverse Transcriptase Inhibitors; D017828:Rifabutin; D016049:Didanosine